H. Léna

7.6k citations

95 papers · 2.3k indexed · 1 hit paper · h-index 20

Impact in

Pulmonary and Respiratory Medicine top 1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Chronic Obstructive Pulmonary Disease (COPD) Research
Oncology top 2%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers

Papers in

Pulmonary and Respiratory Medicine 67
- Lung Cancer Treatments and Mutations 38
- Lung Cancer Diagnosis and Treatment 16
- Tracheal and airway disorders 9
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 6
Oncology 46
- Lung Cancer Research Studies 23
- Colorectal Cancer Treatments and Studies 8
- Cancer Immunotherapy and Biomarkers 8

Co-authors: A. Vergnenègre M. Pérol G. Robinet P. Delaval P. Fournel J. Le Treut C. Belleguic Vincent Lagente
Journals: Journal of Clinical Oncology (11 papers)Lung Cancer (8 papers)Annals of Oncology (6 papers)European Respiratory Journal (4 papers)European Journal of Cancer (4 papers)
Partner nations: France United States Switzerland

In The Last Decade

H. Léna

86 papers receiving 2.2k citations

Hit Papers

align trajectories log scale

Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study 2015 · 430 citations

Peers

Countries citing papers authored by H. Léna

Since Specialization

Citations

This map shows the geographic impact of H. Léna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Léna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Léna more than expected).

Fields of papers citing papers by H. Léna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Léna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Léna. The network helps show where H. Léna may publish in the future.

Co-authorship network

The 25 scholars most cited alongside H. Léna, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with H. Léna Line = papers co-authored together H. Léna links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis Frontiers in Oncology ·Title. by J. A. von Fraunhofer., C. Chouaïd, D. Debieuvre, Clarisse Audigier-Valette, Xavier Quantin, H. Léna, L. Bosquet, Nicolas Girard, Minouk J. Schoemaker, G Koppen, Bruno E. Correia, B.D. Callaghan, M. Daumont, John R. Penrod, Adam Lee, Tomoko Ninomiya	2025	1
2	Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy Respiratory Medicine and Research ·Clarisse Audigier-Valette, Thomas Filleron, D. Debieuvre, H. Léna, M. Pérol, C. Chouaïd, Loraine V. Shepard, Xavier Quantin, Nicolas Girard	2023	5
3	1359P Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients Annals of Oncology ·Marc G. Denis, H. Sprankel, Christine Sagan, Matt Wenman, Audrey Vallée, Jacques Cadranel, Clarisse Audigier-Valette, Pascale Tomasini, Philippe Masson, 马醒华, 洋一杉田, Nicolas Girard, Alexis B. Cortot, Bridget Litts, I. Monnet, M. Marcq, T. Urban, Mao-Yun Lu, H. Léna, Jaafar Bennouna	2023	1
4	Genomic characteristics and clinical significance of CD56+ circulating tumor cells in small cell lung cancer Scientific Reports ·Charles Ricordel, Beatriz Ferreira-Silva, Gerassimos, Nikolaus Gassler, 日立造船K.K.船舶基本設計部, nbspAashima Sodhi, JUAN JOSÉ PARADA HOLGUÍN, Marc Aubry, Michail Slepnev, Haryanti Haryanti, Florence Jouan, Ulrich Jarry, R. Corre, J. Komoto, Thierry Guillaudeux, H. Léna, Aristotelis Chatziioannou, Rémy Pedeux	2023	4
5	First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial European Respiratory Journal ·A. Lavolé, Laurent Greillier, Julien Mazières, I. Monnet, M Kiechle-Bahat, Xavier Quantin, Jean Philippe Spano, H. Léna, Philippe Fraisse, Henri Janicot, Clarisse Audigier-Valette, Alexandra Langlais, Franck Morin, Alain Makinson, Jacques Cadranel	2020	7
6	Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus Journal of Thoracic Oncology ·Rupert Hoogewerf, Alain Lescoat, Alice Ballerie, José Iglesias Urquízar, H. Léna, Charles Ricordel, M. Musthofa A, Célèste Lebbé, Patrick Jégo, Nicolas Belhomme	2020	6
7	Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial Clinical Cancer Research ·Guillaume Eberst, Amélie Anota, Arnaud Scherpereel, Julien Mazières, J. Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro‐Sibilot, Olivier Molinier, H. Léna, F. Rivière, I. Monnet, V. Gounant, Henri Janicot, Radj Gervais, Bing Sun, André van Rossum, Franck Morin, Gérard Zalcman, Virginie Westeel	2019	15
8	OA15.02 Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial Journal of Thoracic Oncology ·Nathalie Baize, I. Monnet, Laurent Greillier, Margaux Geier, H. Léna, Henri Janicot, A. Vergnenègre, Jacky Créquit, R. Lamy, J.B. Auliac, J. Le Treut, H. Le Caer, R. Gervais, Éric Dansin, A. Madroszyk, H. C. Gram, Laila Zakiyatul Zulfa, Roland Schött, Patrick Saulnier, C. Chouaïd	2019	5
9	Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC) Annals of Oncology ·Fabrice Barlési, Anne‐Marie C. Dingemans, James Chih‐Hsin Yang, M. Pakowski, 龚雯, Luigi De Petris, Benjamin Hughes, H. Léna, Walter Bordogna, S Golding, Peter N. Morcos, Bogdan Balas, Ali Zeaiter, Dongwook Kim	2016	11
10	Surrénalectomie pour métastases surrénaliennes : la voie d’abord laparoscopique est-elle bénéfique pour tous les patients ? Progrès en Urologie ·B. Peyronnet, Carlos Iberico, R. Corre, H. Léna, F. Galland, Isabelle Guilhem, Zhu Jiang, X Dong, S. Vincendeau, N. Costedoat‐Chalumeau, Karim Bensalah, A. Manunta	2014	4
11	Cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the preoperative staging of lung cancer, results from the French prospective multicenter trial "EVIEPEB" European Respiratory Journal ·Mathieu Salaün, C. Chouaïd, V. Gounant, M. Febvre, Jean‐Michel Vergnon, V. Jounieaux, C. Fournier, Samy Lachkar, C. Hermant, Bertz Gert, Xavier Quantin, 卢旸, Marielle Faraone, C. Dayen, Charles‐Hugo Marquette, H. Léna, Gérard Zalcman, Nicolas Favrolt, Luc Thiberville	2013	0
12	Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·M. Pérol, C. Chouaïd, David Pérol, Fabrice Barlési, Radj Gervais, Virginie Westeel, Jacky Créquit, H. Léna, A. Vergnenègre, Gérard Zalcman, I. Monnet, H. Le Caer, P. Fournel, L. Falchero, M. Poudenx, F. Vaylet, Céline Ségura‐Ferlay, Mojgan Devouassoux‐Shisheboran, Miquel Tarón, B. Milleron	2012	166
13	Endoscopic Management of Idiopathic Tracheal Stenosis The Annals of Thoracic Surgery ·Jeanne‐Marie Perotin, 幸治山田, Major Singh, 郑雪光, H. Léna, Hervé Dutau, Philippe Ramon, Christine Lorut, Marc Noppen, Jean‐Michel Vergnon, H. Vallerand, Jean‐Claude Mérol, Charles‐Hugo Marquette, François Lebargy, Gaëtan Deslée	2011	4
14	Sarcoïdose pulmonaire apparue sous étanercept Revue des Maladies Respiratoires ·M. Kerjouan, S. Jouneau, H. Léna, Villón Valarezo, B. Desrues, P. Delaval	2011	9
15	Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease Inflammation Research ·Sophie Molet, C. Belleguic, H. Léna, Nicolas Germain, Claude Bertrand, Steven D. Shapiro, Jean‐Michel Planquois, P. Delaval, Vincent Lagente	2005	192
16	Survival of Patients With Bronchiectasis After the First ICU Stay for Respiratory Failure CHEST Journal ·Mathieu Dupont, Arnaud Gacouin, H. Léna, Sylvain Lavoué, Graziella Brinchault, Philippe Delaval, R. Thomas	2004	49
17	Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin–vinorelbine with a cisplatin–vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study Annals of Oncology ·M. Pérol, H. Léna, P. Thomas, G. Robinet, P. Fournel, L Weiskran, C. Belleguic, H. Le Caer, F Blanchon, A. Vergnenègre, J.‐M. Vernejoux, M Gaudemar, K.I.R.A.N. RAVI	2002	16
18	[Fire-eater's lung: report of six cases]. PubMed ·Sophie Birolleau, C. Belleguic, H. Léna, Tong Qi-wei, Hua-Xin Chen	1999	4
19	Tératome mature du médiastin : à propos de deux cas Revue de Pneumologie Clinique ·W. A. Gain, 岩成治, C. Belleguic, N. Nagalakshmi, H. Léna, B. Desrues, 正章井出	1999	3
20	Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin British Journal of Cancer ·B. Desrues, H. Léna, Crispulo Larraga, M.P. Ramée, Louis Toujas, P. Delaval, huaying hu	1995	7

About H. Léna

H. Léna is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Microbiology, Epidemiology and Otorhinolaryngology, having authored 95 papers that have together received 2.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (38 papers), Lung Cancer Research Studies (23 papers), Lung Cancer Diagnosis and Treatment (16 papers), Tracheal and airway disorders (9 papers), Neuroendocrine Tumor Research Advances (8 papers), Colorectal Cancer Treatments and Studies (8 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.7k citations), Oncology (1.2k citations), Otorhinolaryngology (75 citations), Cancer Research (234 citations) and Radiation (117 citations). H. Léna has collaborated with scholars based in France, United States and Switzerland. Frequent co-authors include A. Vergnenègre, M. Pérol, G. Robinet, P. Delaval, P. Fournel, J. Le Treut, C. Belleguic, Vincent Lagente, P. Thomas and Nicolas Germain. Their work appears in journals such as Journal of Clinical Oncology, Lung Cancer, Annals of Oncology, European Respiratory Journal and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact